News | May 16, 2011

Frost & Sullivan Awards GE ‘Price Performance Value’ Leadership in PET Award

May 16, 2011 — GE Healthcare today received the Price Performance Value Leadership Award in PET (positron emission tomography) for North America 2011 from global research organization Frost & Sullivan.

According to Frost & Sullivan, the Price Performance Value Leadership Award is a prestigious recognition of GE Healthcare’s accomplishments in PET. Based on Frost & Sullivan’s analysis of the latest value-based systems currently being offering by PET/CT manufacturers, GE Healthcare’s Optima PET/CT 560 was found to offer a higher price performance value than any other system on the market.

First to the market with PET/CT in 2001, GE Healthcare has built upon its excellence in PET/CT with the Optima PET/CT 560, an innovative scanner designed to address the demands of today’s healthcare environment. Combining superb image quality, high productivity and a patient friendly experience, the Optima PET/CT 560 can continuously deliver ongoing value over time. The system offers efficiency and investment protection with the capability to grow with the future needs of the clinical practice. From the uninterrupted full head to toe exam to the remarkable dose reduction features, the Optima PET/CT 560 was designed to help physicians put patients’ needs first. It includes advanced VUE Point HD intelligent 3-D iterative reconstruction technique to enhance resolution for uncompromised image quality that can help enable clinicians to confidently detect small lesions and increase quantitative accuracy.

According to Frost & Sullivan, despite growing evidence pointing to its superior diagnostic capabilities in many applications within oncology and cardiology, PET/CT’s higher costs have been a deterrent to widespread adoption of this technology since its commercial introduction in 2001. Frost & Sullivan notes that the recent downturn in the U.S. economy and uncertainties surrounding healthcare reform further exasperated this challenge, as these circumstances intensified demand in the market for the more affordable imaging equipment that provides adequate performance in clinically relevant applications. Frost & Sullivan also notes the significant cost-barrier in PET/CT has prompted manufacturers of this technology to become more focused on developing systems that provide the highest performance at the lowest price point possible.

For more information: www.gehealthcare.com

Related Content

Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Nuclear myocardial perfusion scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers. The image shows good clarity with delineation of the left ventricular edge and papillary muscles without cardiac gating.

Nuclear myocardial perfusion scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers. The image shows good clarity with delineation of the left ventricular edge and papillary muscles without cardiac gating.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT | July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
PET/CT, calcium blockages, heart attack risk, Intermountain study, American Heart Association, AHA Scientific Sessions 2016
News | PET-CT | November 15, 2016
Many people who experience chest pain but don’t have a heart attack breathe a big sigh of relief when a stress test...
PET/CT, atherosclerotic plaque detection, Stanford University

Application of dual-modality optical and PET/CT activity-based probe in experimental carotid inflammation model. Coronal noninvasive PET/CT scans of (A) healthy and (B) diseased mice with and without ligated carotid arteries respectively. Inset images show optical ex vivo florescence imagining of (A) healthy and (B) diseased carotid arteries.  PET/CT and optical images courtesy of Xiaowei Ma, Toshinobu Saito and Nimali Withana.

News | PET-CT | November 01, 2016
Researchers at Stanford University have demonstrated for the first time the use of a dual optical and positron emission...
GE Healthcare, Discovery MI PET/CT system, FDA clearance, RSNA 2016
Technology | PET-CT | October 05, 2016
GE Healthcare recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Discovery MI digital...
PET/CT scan, brain stress center, heart disease predictor, ACC.16
News | PET-CT | April 05, 2016
New research shows individuals with a greater degree of activity in the stress center of the brain also have more...
Siemens, Biograph Horizon PET CT, FDA clearance
Technology | PET-CT | January 21, 2016
Siemens Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Biograph...
Toshiba, Celesteion, Steinberg Diagnostic Medical Imaging, U.S., first
News | PET-CT | June 08, 2015
Steinberg Diagnostic Medical Imaging (SDMI) of Las Vegas has bolstered its capabilities by installing the United...
Overlay Init